Anteotech Ltd · ASX:ADO
Anteotech — NWR Virtual Healthcare Conference (March 2026)
16 slides from Anteotech's conference presentation, Mar 26, 2026
Slide 1: Advancing immunodiagnostics through surface chemistry modification
Advancing immunodiagnostics through surface chemistry modification NWR Virtual Healthcare Conference 26 March 2026 Merrill Gray, MD/CEO 26 March 2026 ©AnteoTech Limited 1 1
Slide 2: Disclaimer
Disclaimer IMPORTANT INFORMATION The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. According
Slide 3: Agenda
Agenda • AnteoTech Limited (ASX:ADO) Overview • Life Sciences markets overview • Our Diagnostic Applications • How AnteoBind works • Progress Update • Our customers and partners • Summary 26 March 2026 ©AnteoTech Limited 3 ©AnteoTech Limited
Slide 4: Business Overview (ASX:ADO)
Business Overview (ASX:ADO) Life Sciences • Products, Services - Sales revenue A chemical and • Expertise Patent protected (Family of 8) materials business • Adjacent opportunities Specialising in surface Advanced Battery Technologies chemistry modification . • Products, Technologies, Services – Ear
Slide 5: Life Sciences Markets: An Overview
Life Sciences Markets: An Overview AnteoTech currently does not operate in these Life Sciences sub sectors Global In Vitro Diagnostics (IVD) Pharmaceutical Biotechnology Medical Devices AnteoTech does not operate here Proteins incl. antibodies, polymers DNA RNA etc. IMMUNOASSAYS Other platforms Late
Slide 6: AnteoTech's Life Sciences Markets & Growth Potential
AnteoTech’s Life Sciences Markets & Growth Potential All figures in US$ Billions, as at 2024 Global In Vitro Diagnostics (IVD) Market Value: + $100 B, +7% CAGR to 2029 (9% APAC) Proteins incl. antibodies, polymers etc. IMMUNOASSAYS Market Value: US$56 Billion (65% of the global IVD market), 9% CAGR
Slide 7: Our Applications – Now and New Opportunities
Our Applications – Now and New Opportunities 1. Multiplex Activation kit 2. AnteoBind NXT 3. AnteoBind Biosensor • Sales to the Serum Institute of • Lower cost, higher performing • Supporting the development of India for use in their Luminex in- (more sensitive & reproducible) next-generation house
Slide 8: Bioconjugation is AnteoTech's specialisation!
Bioconjugation is AnteoTech’s specialisation! • Biomolecules1 are the fundamental building blocks of living organisms and essential to biological How AnteoBind NXT coated surfaces functions. improve antibody orientation • The process of attaching biomolecules to other molecules or surfaces is known
Slide 9: AnteoBind NXT's Competitive Advantages in Immunoassays are Significant
AnteoBind NXT’s Competitive Advantages in Immunoassays are Significant Superior Performance: • Up to a 45 x improvement in assay performance (assay signal increase) Simplified Workflow: • One-step activation process at room temperature Cost Optimisation: • Up to 90% reduction in antibody requirement
Slide 10: AnteoBind NXT Supports a Range of Bioconjugations
AnteoBind NXT Supports a Range of Bioconjugations • Antibodies (e.g., mouse/human IgG, IgM) • Viral particles (e.g., HAV) • Virus like particles (e.g., Flavivirus) • Antigen (e.g., COVID-19 spike proteins) • Binding proteins (e.g., Streptavidin, Protein G/A) • Serum protein (e.g., BSA) • Polysacchar
Slide 11: Progress Update
Progress Update • The key factors in market growth, uptake and progress are: • Testing needs to be undertaken to align with specific application needs • Minimum timeframe from sample receipt to results: 2 months • Uptake/Adoption is critically dependent on stage in the product cycle (regulation rela
Slide 12: In terms of potential CLIA market entry
In terms of potential CLIA market entry Novel AnteoBind NXT activation of magnetic particles delivers greater sensitivity and reproducibility (1.8 x improved CLIA signals, relative to Tosyl-activated particles), 1.5 to 6 x lower antibody usage along with 6 x faster activation 4 CLIA Consumables Brea
Slide 13: Who already uses AnteoBind and works with us?
Who already uses AnteoBind and works with us? Distributors Research Partners 26 March 2026 ©AnteoTech Limited 13
Slide 14: Summary
Summary • AnteoBind advances immunodiagnostics through surface chemistry modification • Fast, enabled by its unique, proprietary chemistry • Supports lower cost end use applications through reduced antibody usage, by minimising waste and improving workflows • Delivers improved test performance. Thro
Slide 15: Questions?
Questions? Questions? Contact: Contact: Merrill Gray Merrill Gray merrill.gray@anteotech.com merrill.gray@anteotech.com +61 (07) 3219 0085 +61 (07) 3219 0085 www.anteotech.com www.anteotech.com 26 March 2026 ©AnteoTech Limited 3 December 2025 ©AnteoTech Limited 15 15
Slide 16: Want to know more about our Technology?
Want to know more about our Technology? LINK: https://www.youtube.com/watch?v=gaCM0wokQLI “cross-linking” 26 March 2026 ©AnteoTech Limited 16 16
AnteoTech — NWR Virtual Healthcare Conference (March 2026) on 6ix